Skip to main content

Drug Interactions between oteseconazole and talazoparib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

talazoparib oteseconazole

Applies to: talazoparib and oteseconazole

MONITOR: Coadministration with inhibitors of breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of this efflux membrane transporter. However, the effect of BCRP inhibitors on the pharmacokinetics of talazoparib has not been studied in vivo.

MANAGEMENT: Caution is recommended when talazoparib is coadministered with inhibitors of BCRP. Some authorities advise that concomitant use of talazoparib with potent BCRP inhibitors such as cyclosporine should be avoided (UK). Patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2018) "Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group

Drug and food interactions

Moderate

oteseconazole food

Applies to: oteseconazole

ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of oteseconazole. When administered with a high-fat, high-calorie meal (800 to 1000 calories; 50% fat), oteseconazole peak plasma concentration (Cmax) and systemic exposure (AUC 0-72h) increased by 45% and 36%, respectively. However, no significant differences were observed with a low-fat, low-calorie meal.

MANAGEMENT: Oteseconazole should be administered with food.

References (1)
  1. (2022) "Product Information. Vivjoa (oteseconazole)." Mycovia Pharmaceuticals, Inc.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer